Knight Other Current Assets vs Net Receivables Analysis
GUD Stock | CAD 5.22 0.04 0.77% |
Knight Therapeutics financial indicator trend analysis is infinitely more than just investigating Knight Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Knight Therapeutics is a good investment. Please check the relationship between Knight Therapeutics Other Current Assets and its Net Receivables accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Other Current Assets vs Net Receivables
Other Current Assets vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Knight Therapeutics Other Current Assets account and Net Receivables. At this time, the significance of the direction appears to have strong relationship.
The correlation between Knight Therapeutics' Other Current Assets and Net Receivables is 0.6. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Knight Therapeutics, assuming nothing else is changed. The correlation between historical values of Knight Therapeutics' Other Current Assets and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Knight Therapeutics are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Other Current Assets i.e., Knight Therapeutics' Other Current Assets and Net Receivables go up and down completely randomly.
Correlation Coefficient | 0.6 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Net Receivables
Most indicators from Knight Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Knight Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Knight Therapeutics' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 17th of December 2024, Enterprise Value Multiple is likely to grow to 14.58, while Selling General Administrative is likely to drop about 23.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 3.6M | 6.6M | 12.5M | 9.4M | Depreciation And Amortization | 47.9M | 62.6M | 50.4M | 52.9M |
Knight Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Knight Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Knight Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.3B | 1.0B | 991.9M | 1.1B | 945.5M | 952.1M | |
Total Stockholder Equity | 810.7M | 886.2M | 842.0M | 825.9M | 746.9M | 823.4M | |
Net Debt | (107.1M) | (173.4M) | (45.0M) | 6.0M | 10.3M | 10.8M | |
Cash | 169.3M | 229.6M | 86.0M | 71.7M | 58.8M | 55.8M | |
Cash And Short Term Investments | 430.6M | 411.3M | 163.0M | 191.2M | 154.4M | 146.7M | |
Common Stock Shares Outstanding | 140.1M | 132.0M | 124.5M | 114.9M | 107.5M | 123.8M | |
Liabilities And Stockholders Equity | 1.3B | 1.0B | 991.9M | 1.1B | 945.5M | 952.1M | |
Total Current Assets | 698.2M | 554.6M | 307.3M | 395.6M | 365.1M | 556.5M | |
Common Stock | 723.8M | 694.4M | 628.9M | 599.1M | 540.0M | 625.0M | |
Other Current Liab | 185.8M | 1.3M | 2.0M | 15.0M | 7.9M | 7.5M | |
Total Current Liabilities | 350.8M | 114.1M | 105.3M | 141.3M | 114.0M | 96.9M | |
Property Plant And Equipment Net | 29.0M | 26.2M | 29.9M | 22.6M | 17.9M | 14.0M | |
Current Deferred Revenue | 39.9M | 14.6M | 9.7M | 1.2M | 1.4M | 1.3M | |
Retained Earnings | 52.2M | 174.5M | 191.6M | 161.8M | 150.9M | 178.6M | |
Accounts Payable | 72.8M | 44.5M | 65.3M | 106.1M | 85.4M | 89.6M | |
Non Current Assets Total | 607.1M | 485.0M | 684.6M | 659.2M | 580.4M | 435.2M | |
Non Currrent Assets Other | 52.7M | 47.3M | 47.9M | 48.2M | 7.8M | 7.4M | |
Net Receivables | 111.7M | 82.0M | 67.4M | 110.2M | 98.2M | 55.5M | |
Short Term Investments | 261.3M | 181.7M | 77.0M | 119.5M | 95.7M | 172.8M | |
Inventory | 70.9M | 56.5M | 72.4M | 92.5M | 91.8M | 96.4M | |
Other Current Assets | 85.0M | 4.8M | 4.5M | 1.7M | 20.6M | 13.2M | |
Other Stockholder Equity | 17.2M | 18.8M | 21.9M | 23.8M | 26.0M | 17.1M | |
Total Liab | 390.2M | 153.4M | 149.9M | 229.0M | 198.6M | 130.2M | |
Accumulated Other Comprehensive Income | 17.4M | (1.5M) | (376K) | 41.3M | 29.9M | 16.4M | |
Short Term Debt | 52.3M | 53.6M | 28.3M | 20.3M | 19.6M | 22.7M | |
Intangible Assets | 173.4M | 156.5M | 350.3M | 338.8M | 290.0M | 149.3M | |
Non Current Liabilities Total | 39.4M | 39.4M | 44.6M | 87.7M | 84.6M | 88.8M |
Pair Trading with Knight Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Knight Stock
Moving against Knight Stock
0.9 | BOFA | Bank of America | PairCorr |
0.89 | JPM | JPMorgan Chase | PairCorr |
0.85 | RY-PS | Royal Bank | PairCorr |
0.84 | RY-PM | Royal Bank | PairCorr |
0.84 | RY-PJ | Royal Bank | PairCorr |
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Knight Stock
Balance Sheet is a snapshot of the financial position of Knight Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Knight Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Knight Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Knight currently owns. An asset can also be divided into two categories, current and non-current.